Drug

4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine).

4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). is a pharmaceutical drug with 1 clinical trials. Currently 1 active trials ongoing.

Find Trials

Total Trials

Max Phase

—

Type

DRUG

Molecule

—

Success Metrics

Active Trials

1(100%)

Phase Distribution

Ph phase_3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

Phase 3Large-scale testing

1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Detailed Status

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

recruiting1100%

Recent Activity

1 active trials

Showing 1 of 1

recruitingphase_3

The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia

NCT07232134

Clinical Trials (1)

Showing 1 of 1 trials

NCT07232134Phase 3

The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia

Recruiting

All 1 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 1